Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution
- PMID: 17147082
Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution
Abstract
Aim: To test the prognostic significant of clinicopathologic factors in patients affected by well-differentiated thyroid carcinoma (WDTC).
Methods: A retrospective review of patients treated for WDTC (thyroidectomy and a radioactive iodine (1131) thyroid ablation) at our Institute with a minimum of 10 years of follow-up was carried out. The unfavourable prognosis at the end of the follow-up was defined as persistence/recurrence of WDTC or death due to the cancer.
Results: 234 patients (162 female, 72 male), mean age of 47.6 +/- 166 years, were included in this study (mean follow-up 158.4 +/- 34.8 months): 78 (33.4%) subjects had persistence/recurrence of neoplasia while 5 (2.1%) died for cancer. The multivariate regression showed that prognostic factors were old age, size of cancer, detectable thyroglonulin levels six months after metabolic ablation, and DeGroot staging system.
Discussion: Our mortality rate is lower (2.1%) than reported in literature (10%): this could be explained by the different pathological classification and treatment. The mortality rate appears higher in patients treated with emitiroidectomy and TSH suppressive therapy than in those with total thyroidectomy and I131 ablation. Even if we have chosen an "aggressive" therapy and our mortality rate is lower, one third of patients have persistence/recurrence of cancer: it seems that tumour recurrence rate better reflects clinical problems related to cancer.
Conclusion: WDTC has with a good disease-specific survival but a significant recurrence rate. The most important predictors are the old age and the size of lesion. We suggest a radical surgery followed by radiometabolic ablation in all patients with WDTC.
Similar articles
-
The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.Cancer. 1998 Jan 15;82(2):375-88. Cancer. 1998. PMID: 9445196
-
High recurrent rate of multicentric papillary thyroid carcinoma.Ann Surg Oncol. 2009 Sep;16(9):2609-16. doi: 10.1245/s10434-009-0565-7. Epub 2009 Jun 16. Ann Surg Oncol. 2009. PMID: 19533244 Clinical Trial.
-
Management and outcome of recurrent well-differentiated thyroid carcinoma.Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24. doi: 10.1001/archotol.130.7.819. Arch Otolaryngol Head Neck Surg. 2004. PMID: 15262757
-
[Prospective therapy study in differentiated thyroid carcinoma].Schweiz Med Wochenschr. 1995 Nov 18;125(46):2226-36. Schweiz Med Wochenschr. 1995. PMID: 8525342 Review. German.
-
[Long-term course in differentiated thyroid gland carcinoma].Schweiz Med Wochenschr. 1992 Nov 28;122(48):1843-57. Schweiz Med Wochenschr. 1992. PMID: 1462145 Review. German.
Cited by
-
Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma.Acta Otorhinolaryngol Ital. 2009 Dec;29(6):312-6. Acta Otorhinolaryngol Ital. 2009. PMID: 20463835 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical